Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals plans a $350 M share offering amid strong clinical wins—could boost its oncology and endocrine pipeline, raising investor interest and price targets.

Crinetics Pharmaceuticals Inc. is poised for growth after announcing regulatory milestones, a strategic partnership, and the approval of its acromegaly drug, but questions remain about its sustainability, valuation, and competitive positioning.

Crinetics Pharmaceuticals Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for endocrine diseases and cancers, with a market capitalization of $3.14 billion.

Crinetics Pharmaceuticals and Keros Therapeutics are facing scrutiny from investors and analysts, with Crinetics awaiting its Q1 earnings report and Keros Therapeutics facing calls for restructuring from its largest shareholder, ADAR1 Capital Management.